Unicycive Therapeutics, Inc. (UNCY) Stock Analysis & Investment Frameworks
Unicycive Therapeutics, Inc. (UNCY) stock analysis on Invetso. Review Unicycive Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Unicycive Therapeutics, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Unicycive Therapeutics, Inc. Key Financial Metrics
- Market Cap: $106.01M
- Revenue: $N/A
- ROE: -88.81%
- ROIC: -61.44%
- Dividend Yield: N/A
About Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
Unicycive Therapeutics, Inc. Investment Frameworks
Invetso analyzes Unicycive Therapeutics, Inc. (UNCY) across the following frameworks:
- Unicycive Therapeutics, Inc. 10Y Growth Potential
- Unicycive Therapeutics, Inc. Scenario Analysis
- Unicycive Therapeutics, Inc. Risks & Opportunities
- Unicycive Therapeutics, Inc. Economic Moat
- Unicycive Therapeutics, Inc. Business Model
- Unicycive Therapeutics, Inc. Management
- Unicycive Therapeutics, Inc. SWOT Analysis
- Unicycive Therapeutics, Inc. Porter's 5 Forces
- Unicycive Therapeutics, Inc. PESTLE Analysis
- Unicycive Therapeutics, Inc. ESG Analysis